XRCC1 and ovarian cancer: For example, inhibiting ARL6IP5-XRCC1-mediated DNA single-strand-break repair (SSBR) could reverse the resistance of ovarian cancer cells to Cx-platin-Cl and Cx-DN604-Cl (two Pt(IV) prodrugs), and restore the sensitivity of ovarian cancer cells to cisplatin [67].